Welcome to our dedicated page for PROCEPT BioRobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics reported second quarter 2026 revenue of $94.5 million, up 19% year over year, driven by higher U.S. handpiece, system and international revenue. U.S. revenue reached $83.4 million, with U.S. procedures over 13,100, an increase of approximately 21%. The company delivered 65 U.S. HYDROS systems, including 14 replacements, and handpieces represented about 98% of U.S. procedures.
Gross margin improved to 66%, supported by higher U.S. pricing and a $2.9 million tariff refund, while operating expenses rose to $89.8 million as the company invested in its commercial organization, BPH platform innovation and the WATER IV prostate cancer trial. Net loss widened to $26.9 million (adjusted EBITDA loss $11.3 million), and cash, cash equivalents and restricted cash totaled approximately $231 million at June 30, 2026.
For full year 2026, PROCEPT reiterates revenue guidance of $390 million to $410 million and gross margin of about 65%, expects U.S. procedure volume of 54,000-56,000, and now forecasts an adjusted EBITDA loss of $35 million to $30 million. Management also highlighted record HYDROS placements, completion of enrollment in the WATER IV study and a strengthened AUA guideline recommendation for Aquablation therapy.
BlackRock, Inc. reports its beneficial ownership of common stock of PROCEPT BioRobotics Corp on an amended Schedule 13G. BlackRock and certain of its business units collectively beneficially own 4,646,656 shares of PROCEPT BioRobotics common stock, representing 8.2% of the outstanding class.
BlackRock has sole voting power over 4,558,571 shares and sole dispositive power over all 4,646,656 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have rights to dividends and sale proceeds, but no single person has an interest exceeding five percent of PROCEPT BioRobotics’ outstanding common shares. The filing is signed by Spencer Fleming, Managing Director of BlackRock, Inc.
PROCEPT BioRobotics director Antal Rohit Desai received new equity awards as compensation. He was granted 3,315 restricted stock units, each representing one future share of Common Stock, increasing his reported Common Stock holdings to 38,467 shares. He also received a stock option for 5,853 shares at an exercise price of $28.78 per share. Both the RSUs and the option vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting following that date, subject to his continued service.
PROCEPT BioRobotics Corp director Amy M. Dodrill received equity-based compensation consisting of restricted stock units and stock options. She was granted 3,315 restricted stock units, each representing one share of common stock, increasing her direct common share holdings to 10,941 shares after the grant.
Dodrill was also granted 5,853 stock options with an exercise price of 28.78 per share, all of which remain outstanding and expire on June 8, 2036. Both the RSUs and options vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting following that date, subject to her continued service.
PROCEPT BioRobotics director Mary Garrett received new equity awards. She was granted 3,315 restricted stock units, bringing her direct common stock holdings to 17,700 shares after the award. She also received a stock option for 5,853 shares at an exercise price of $28.78, expiring on June 8, 2036.
Both the RSUs and the option vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, if she continues serving until that vesting date.
PROCEPT BioRobotics director Taylor C. Harris received new equity awards as part of director compensation. He was granted 3,315 restricted stock units, each representing one share of Common Stock, and 5,853 stock options with an exercise price of $28.78 per share. Both the RSUs and options vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service. After this award, Harris directly holds 102,491 shares of Common Stock.
PROCEPT BioRobotics Corp director Elisabeth Sandoval received new equity compensation awards. On June 9, 2026, she was granted 3,315 restricted stock units (RSUs), each representing one share of common stock, and stock options for 5,853 shares at an exercise price of $28.78 per share.
The RSUs and options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to her continued service. After the RSU grant, Sandoval directly owns 15,876 shares of common stock. The newly granted options expire on June 8, 2036.
PROCEPT BioRobotics Corp director Frederic H. Moll received new equity awards as part of his compensation. He acquired 3,315 restricted stock units, each representing one future share of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to continued service.
He was also granted a stock option for 5,853 shares of common stock at an exercise price of $28.78 per share, vesting on the same schedule. Following the RSU award, Moll directly holds 866,474 shares of common stock, indicating this is a routine, compensation-related equity grant rather than an open-market purchase or sale.
PROCEPT BioRobotics director Thomas M. Prescott received new equity awards in the form of restricted stock units and stock options. He was granted 3,315 restricted stock units, each representing a right to receive one share of Common Stock, and now holds 7,211 shares of Common Stock following the award. The RSUs vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service.
He was also granted stock options for 5,853 shares of Common Stock at an exercise price of $28.78 per share, vesting on the same schedule and expiring on June 8, 2036. These are compensation-related grants rather than open‑market purchases or sales.
PROCEPT BioRobotics director Dan Puckett received new equity awards. He was granted 3,315 restricted stock units, each representing a right to one share of common stock, increasing his direct common stock holdings to 8,791 shares after the grant.
He was also granted stock options for 5,853 shares of common stock at an exercise price of $28.78 per share, expiring on June 8, 2036. Both the RSUs and options vest in full on the earlier of one year from the June 9, 2026 grant date or the next annual meeting, subject to continued service.